Gilead agreed to acquire PepStar Therapeutics’ HCXT-2001 oral IL-23 receptor program for $1.275 billion in upfront payments, according to the deal summary provided. HCXT-2001 is described as an oral macrocyclic peptide inhibitor in Phase 1 trials. Gilead will receive worldwide rights and positions the program as a potentially differentiated daily oral route to inhibit the IL-23 pathway, either alone or in combination strategies for inflammatory bowel disease. The transaction strengthens Gilead’s inflammation and immunology portfolio and targets a market niche dominated by advanced biologics and infusions—where oral dosing could change adherence and logistics. Bottom line: Gilead is paying for modality differentiation—oral IL-23R inhibition—rather than another injectable development track.